Characteristics Associated With Decreased or Increased Mortality Risk From Glycemic Therapy Among Patients With Type 2 Diabetes and High Cardiovascular Risk: Machine Learning Analysis of the ACCORD Trial
- 26 December 2017
- journal article
- research article
- Published by American Diabetes Association in Diabetes Care
- Vol. 41 (3), 604-612
- https://doi.org/10.2337/dc17-2252
Abstract
OBJECTIVE Identifying patients who may experience decreased or increased mortality risk from intensive glycemic therapy for type 2 diabetes remains an important clinical challenge. We sought to identify characteristics of patients at high cardiovascular risk with decreased or increased mortality risk from glycemic therapy for type 2 diabetes using new methods to identify complex combinations of treatment effect modifiers. RESEARCH DESIGN AND METHODS The machine learning method of gradient forest analysis was applied to understand the variation in all-cause mortality within the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial (N = 10,251), whose participants were 40–79 years old with type 2 diabetes, hemoglobin A1c (HbA1c) ≥7.5% (58 mmol/mol), cardiovascular disease (CVD) or multiple CVD risk factors, and randomized to target HbA1c 1c glycation index (HGI; observed minus expected HbA1c derived from prerandomization fasting plasma glucose), other biomarkers, history, and medications. RESULTS The analysis identified four groups defined by age, BMI, and HGI with varied risk for mortality under intensive glycemic therapy. The lowest risk group (HGI 2, age P = 0.038; number needed to treat: 43), whereas the highest risk group (HGI ≥0.44) had an absolute mortality risk increase of 3.7% attributable to intensive therapy (95% CI 1.5 to 6.0; P < 0.001; number needed to harm: 27). CONCLUSIONS Age, BMI, and HGI may help individualize prediction of the benefit and harm from intensive glycemic therapy.Funding Information
- National Institute on Minority Health and Health Disparities (DP2-MD-010478, U54-MD-010724)
- American Heart Association (17MCPRP33670728)
- National Institute for Diabetes and Digestive and Kidney Disease (U01-DK-098246, R18-DK-10273, K23-DK-109200)
This publication has 33 references indexed in Scilit:
- Evaluation of Evidence of Statistical Support and Corroboration of Subgroup Claims in Randomized Clinical TrialsJAMA Internal Medicine, 2017
- Effects of intensive glucose control on microvascular outcomes in patients with type 2 diabetes: a meta-analysis of individual participant data from randomised controlled trialsThe Lancet Diabetes & Endocrinology, 2017
- Detecting Heterogeneous Treatment Effects to Guide Personalized Blood Pressure TreatmentAnnals of Internal Medicine, 2017
- 6. Glycemic TargetsDiabetes Care, 2016
- Liraglutide and Cardiovascular Outcomes in Type 2 DiabetesThe New England Journal of Medicine, 2016
- HbA1covertesting and overtreatment among US adults with controlled type 2 diabetes, 2001-13: observational population based studyBMJ, 2015
- Effects of Randomization to Intensive Glucose Control on Adverse Events, Cardiovascular Disease, and Mortality in Older Versus Younger Adults in the ACCORD TrialDiabetes Care, 2014
- Using Internally Developed Risk Models to Assess Heterogeneity in Treatment Effects in Clinical TrialsCirculation: Cardiovascular Quality and Outcomes, 2014
- The Impact of Frequent and Unrecognized Hypoglycemia on Mortality in the ACCORD StudyDiabetes Care, 2012
- Effects of Intensive Glucose Lowering in Type 2 DiabetesThe New England Journal of Medicine, 2008